RxDoctor Payments Data

Courtney Hindes, PA

Physician Assistant · Lexington, NCNPI 1598437121

Payments from drug & device makers

$3,686in general payments, 2019–2025

Across 233 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$703
  • AbbVie$551
  • Lilly USA, LLC$362
  • Ironwood Pharmaceuticals, Inc$209
  • Pfizer$176
  • GSK$174
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,686 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$45,512
Medicare patients
201
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide113$121,414
OzempicSemaglutide73$87,828
JardianceEmpagliflozin70$50,329
Soliqua 100-33Insulin Glargine/Lixisenatide32$33,472
EliquisApixaban39$33,036
FarxigaDapagliflozin Propanediol45$29,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,729
TrulicityDulaglutide16$27,107
Tresiba Flextouch U-200Insulin Degludec20$24,242
SymbicortBudesonide/Formoterol Fumarate52$17,156
RybelsusSemaglutide16$16,711
JanuviaSitagliptin Phosphate24$15,421
NamzaricMemantine Hcl/Donepezil Hcl14$12,495
MyrbetriqMirabegron14$8,180
Albuterol Sulfate HfaAlbuterol Sulfate293$6,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$362$148,521129 claims
Novo NordiskOzempic, Rybelsus$703$104,53989 claims
Boehringer IngelheimJardiance, Spiriva Respimat$149$55,84581 claims
AstraZenecaFarxiga, Symbicort$101$47,10597 claims
GSKTrelegy Ellipta, Incruse Ellipta$174$35,07857 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$94$33,47232 claims
PfizerEliquis$176$33,03639 claims
AbbVieNamzaric$551$12,49514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Lexington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →